US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
biotech · Relapsed or Refractory B-cell Malignancies · Solid Tumor · RXRX
RECURSION PHARMACEUTICALS
RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Staten Island, USA HQ
11 Employees
Public company Type
RXRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Staten Island, USA
- Employees
- 11
- Programs
- 9
- Drugs
- 2
- Patents
- 4
RECURSION PHARMACEUTICALS pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
RECURSION PHARMACEUTICALS drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist